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Abstract
Background: Niemann Pick disease type C1 is a neurodegenerative disease caused by mutations in the NPC1 gene, which
result in accumulation of unesterified cholesterol and glycosphingolipids in the endosomal-lysosomal system as well as
limiting membranes. We have previously shown the corneal involvement in NPC1 pathology in form of intracellular
inclusions in epithelial cells and keratocytes. The purpose of the present study was to clarify if these inclusions regress
during combined substrate reduction- and by-product therapy (SRT and BPT).
Methodology/Principal Findings: Starting at postnatal day 7 (P7) and thereafter, NPC1 knock-out mice (NPC1
2/2) and wild
type controls (NPC1
+/+) were injected with cyclodextrin/allopregnanolone weekly. Additionally, a daily miglustat injection
started at P10 until P23. Starting at P23 the mice were fed powdered chow with daily addition of miglustat. The sham group
was injected with 0.9% NaCl at P7, thereafter daily starting at P10 until P23, and fed powdered chow starting at P23. For
corneal examination, in vivo confocal laser-scanning microscopy (CLSM) was performed one day before experiment was
terminated. Excised corneas were harvested for lipid analysis (HPLC/MS) and electron microscopy. In vivo CLSM
demonstrated a regression of hyperreflective inclusions in all treated NPC1
2/2mice. The findings varied between individual
mice, demonstrating a regression, ranging from complete absence to pronounced depositions. The reflectivity of inclusions,
however, was significantly lower when compared to untreated and sham-injected NPC1
2/2 mice. These confocal findings
were confirmed by lipid analysis and electron microscopy. Another important CLSM finding revealed a distinct increase of
mature dendritic cell number in corneas of all treated mice (NPC1
2/2 and NPC1
+/+), including sham-treated ones.
Conclusions/Significance: The combined substrate reduction- and by-product therapy revealed beneficial effects on the
cornea. In vivo CLSM is a non-invasive tool to monitor disease progression and treatment effects in NPC1 disorder.
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Introduction
Lysosomal storage diseases (LSDs) are a form of metabolic
disorder caused by inherited deficiencies of specific lysosomal
enzymes, which lead to the accumulation of nonmetabolized
macromolecules [1]. The frequency of LSDs as a group varies
among populations from 7 to 25 per 100.000 [2].
Niemann Pick disease type C1 is a LSD of autosomal recessive
inheritance, caused by mutations in the NPC1 gene that encodes
for a large transmembrane protein [3]. In Western Europe, the
birth incidence of NPC1 has been estimated to be 1 in 150.000
[4]. Cells harbouring mutations in NPC1 gene accumulate low-
density lipoprotein (LDL)-derived cholesterol in late endosomes/
lysosomes and exhibit defects in lipid trafficking and storage [5,6].
Affected patients develop ataxia, motor dysfunction and organo-
megaly [7,8]. The neuropathological features are characterized by
progressive loss of Purkinje cells in the cerebellum, and neurons in
the basal ganglia and brain stem [9,10]. Also, cytoskeletal changes
have been demonstrated in neurons in form of neurofibrillary
tangles, consisting of hyperphosphorylated tau protein [11]. The
initial clinical manifestations of NPC1 disease vary strongly, being
neurological, pulmonary or hepatic in nature [12]. The lifespan of
patients varies between a few days until over 60 years of age - the
majority of cases, however, die between 10 and 25 years of age
[13].
One possibility to alleviate the severity of disease could be
blocking the intestinal absorption of cholesterol with Ezetimibe
[14] or inhibition of protein hyperphosphorylation. Blocking of
cyclin-dependent kinases reveal a strong inhibitory effect on
protein phosphorylation, being favourable for neural cell survival
and thus improving locomotor defects in NPC1 knock-out
(NPC1
2/2) mice [15]. However, the inhibition of extracellular
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28418signal regulated kinases did not alter neurological indices of NPC1
disease in this mouse model [16].
A very promising approach for the treatment of NPC1 is the
substrate reduction therapy (SRT) with the blood-brain barrier
crossing small molecule miglustat (N-butyldeoxynojirimycin),
which has been reported to reduce lipid accumulation in
NPC1
2/2 mice, thus leading to delay in onset of clinical signs
and increasing lifespan [17]. Administration of miglustat has
normalized lipid trafficking and improved clinical signs in human
patients, both children and adults [18–22].
The second therapeutic approach, so called by-product therapy
(BPT) utilizes the neurosteroid allopregnanolone, which is
deficient in NPC1
2/2 mice [23]. Allopregnanolone, dissolved in
2-hydroxypropyl-ß-cyclodextrin (CD), led to delay in clinical onset
and decrease of ganglioside deposition [24]. It could be shown that
combination of both approaches (miglustat and cyclodextrin/
allopregnanolone) had a significant synergic effect in ameliorating
disease progression [25]. Very interestingly, the same study
demonstrated that administration of vehicle cyclodextrin even at
low concentrations had a greater therapeutic effect in NPC1
2/2
mice than did the administration of allopregnanolone alone.
Recently, we have reported on the visualization of hyperre-
flective inclusions in corneal epithelial cells in NPC1 deficient mice
by in vivo confocal laser-scanning microscopy (CLSM), a non-
invasive technique [26]. The present study was designed for
investigation of NPC1
2/2 mice corneas after combined SRT and
BRT, including cyclodextrin, allopregnanolone and miglustat
(Cyclo/ALLO/miglustat). We hypothesized that treatment effects
could be monitored by this in vivo imaging possibility, thus, giving
researchers and clinicians an additional tool for monitoring disease
lapse and treatment efficiency among neurological and biochem-
ical examinations.
Results
In vivo CLSM
In vivo CLSM allowed visualization of all corneal layers at the
cellular level (Fig. 1).
The most superficial cells of a normal cornea (NPC1
+/+ mice)
were visualised as polygonal structures with bright cytoplasm and
hyperreflective nuclei (Fig. 1A). The smaller basal cells were
characterized by bright cell borders and a dark cytoplasm, without
distinguishable nuclei (Fig. 1B). The corneal stroma demonstrated
a dark background (extracellular matrix), reflective interconnected
stellate structures, corresponding to keratocyte cell bodies and
hyperreflective stromal nerves (Fig. 1C). The endothelial mono-
layer consisted of hexagonal cells with bright cytoplasm, displaying
minimal variations in size and morphology (Fig. 1D).
Figure 2 demonstrates structural changes affecting basal cells in
NPC1 disease. When compared to the normal morphology of
basal epithelial cells seen in NPC1
+/+ mice (Fig. 2A), the basal cells
in NPC1
2/2 cells showed no distinguishable borders and
cytoplasm, but were identified as units with hyperreflective content
(Fig. 2B).
Figure 1. In vivo CLSM of NPC1
+/+ mouse cornea. (A) - superficial epithelial cells with hyperreflective nuclei and dark cytoplasm. (B) - basal
epithelial cells with polygonal morphology and bright cell borders. (C) - corneal stroma with dark ground substance and hyperreflective nerves.
(D) - hexagonal endothelial cells with highly reflective cytoplasm and dark cell borders. Bar: 50 mm.
doi:10.1371/journal.pone.0028418.g001
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epithelial cells after Cyclo/ALLO/miglustat treatment. Impor-
tantly, the corneal response to the treatment varied strongly
between individual mice. We therefore classified the inclusions in a
grading system. From out of 14 Cyclo/ALLO/miglustat-treated
NPC1
2/2 mice 3 almost lacked inclusions (grade 0, Fig. 3A).
Among residual 11 NPC1
2/2 mice, grade 1 (up to 25% of cells
affected) occurred in 5 (Fig. 3B) and grade 2 (up to 50% of cells
affected) in 6 mice (Fig. 3C). In sham-treated NPC1
2/2 corneas
the depositions of very high intensity affected almost every single
cell (grade 3, Fig. 3D). To date, the grade 3 was never observed in
Cyclo/ALLO/miglustat-treated NPC1
2/2 mice. These findings
are summarized in a graph (Fig. 3E), which clearly shows the
percentage of NPC1
2/2 mice involved in a grading system from 0
to 3, before and after treatment.
These observations become more obvious in oblique sections of
the epithelium (Fig. 4). The oblique section shows clearly
hyperreflective inclusions in intermediate and basal cells in
NPC1
2/2 corneas (Fig. 4B). The corneas of some Cyclo/
ALLO/miglustat-treated NPC1
2/2 mice revealed almost no
inclusions (Fig. 4C) when compared to controls (Fig. 4A), whereas
corneas from other treated NPC1
2/2 mice revealed more
pronounced inclusions (Fig. 4D, grade 2), whose intensity was,
however, much lower when compared to untreated ones.
Normally, there are only very few dendritic cells (DCs) observed
in the central mouse cornea. They become obvious only after
careful examination of the entire central part of the cornea. A
considerable increase in DC number was noted in NPC1
2/2
corneas (Fig. 5A). After Cyclo/ALLO/miglustat treatment, in
both groups (NPC1
2/2 and NPC1
+/+) in vivo CLSM revealed
numerous mature DCs with processes arranged in a meshwork
(Fig. 5B and C). Interestingly, also the sham-treated group
revealed very pronounced DCs (Fig. 5D). The number of DCs
was quantified in all groups (Table 1). In the NPC1
+/+ group
(Fig. 6A) the number of DCs increased significantly from 963t o
4565 cells/mm
2 after Cyclo/ALLO/miglustat therapy
(p,0.0001). Also the sham-treated NPC1
+/+ mice revealed an
increase to 3463 cells/mm
2, which was statistically significant
when compared to pre-treatment value (p,0.0001). Similarly, the
NPC1
2/2 corneas (Fig. 6B) demonstrated a significant increase of
DC number from 2965 cells/mm
2 to 7266 cells/mm
2
(p,0.0001) after Cyclo/ALLO/miglustat therapy and to 5064
cells/mm
2 (p,0.0001) after sham treatment. Notably, the increase
of DC number was more pronounced after Cyclo/ALLO/
miglustat therapy: the comparison of both forms of therapy by
mean of DC number revealed a significant difference, both for
NPC1
+/+ (p=0.00068) and NPC1
2/2 (p=0.000018) mice
corneas.
High Performance Liquid Chromatography/Mass
spectroscopy (HPLC/MS)
The levels of two different isoforms of disialotetrahexosylgan-
glioside 2-GM2 (GM2 C20-0 and GM2 C18-0) were negligible
(lower than level of quantification-LLOQ, less than 4 mg/g) in
NPC1
+/+ mice corneas (n=4). Therefore it was not possible to
evaluate the impact of Cyclo/ALLO/miglustat therapy on GM2
level in NPC1
+/+ corneas. In contrast, the NPC1
2/2 corneas
(n=4) revealed a highly increased level of GM2 isoforms before
treatment, reaching 12 and 14 mg per g tissue for GM2 C20-0 and
GM2 C18, respectively. After Cyclo/ALLO/miglustat therapy the
HPLC/MS analysis demonstrated that the GM2 C20-0 and GM2
C18-0 levels were dramatically reduced in Cyclo/ALLO/miglu-
stat-treated NPC1
2/2 mice corneas, reaching 3 and 2 mg per g
tissue, respectively (Fig. 7A). For both, C20-0 and C18-0 this
reduction reached significance (p=0.02).
The corneas of Cyclo/ALLO/miglustat-treated NPC1
+/+ and
NPC1
2/2 mice revealed also a reduction in free cholesterol level
in both groups (Fig. 7B). The level of cholesterol was reduced from
19846164 mg/g (before treatment) to 13676493 mg/g (after
Cyclo/ALLO/miglustat treatment) in NPC1
+/+ mice and from
27926599 mg/g (before treatment) to 21656248 mg/g (after
Cyclo/ALLO/miglustat treatment) in NPC1
2/2 treated ones.
This decrease was, however, not significant for both, NPC1
+/+ and
NPC1
2/2 mice corneas (p=0.0564 for NPC1
+/+ group and
p=0.083 for NPC1
2/2 group).
The comparison of free cholesterol level between NPC1
+/+ and
NPC1
2/2 group revealed a statistically not significant increase in
NPC1
2/2 group before treatment. After Cyclo/ALLO/miglustat
therapy the difference in free cholesterol level was still relatively
small between NPC1
+/+ and NPC1
2/2, reaching, however,
significance (p=0.02).
As mentioned above, the corneas for lipid analysis were
harvested from randomly chosen mice. To verify the treatment
effects, a comparison between HPLC data and in vivo CLSM
findings was performed.
By comparison of absolute values of HPLC/MS (Table 2) with in
vivo CLSM findings a very interesting observation was made: those
Figure 2. In vivo CLSM of basal epithelial cells in NPC1
+/+ and NPC1
2/2 mouse cornea. Compared to the normal epithelium of NPC1
+/+
mice (A), the basal epithelial cells of NPC1
2/2 mice revealed no visible cell borders and excessive hyperreflective inclusions (B). Bar: 50 mm.
doi:10.1371/journal.pone.0028418.g002
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alsohad negligibleGM2valuesinHPLC/MS(LLOQ),whereasthe
micewith morepronounced accumulations inCLSM demonstrated
detectable amounts of both isoforms of GM2, which were, however,
strongly decreased when compared to pre-treatment values.
Electron microscopy
In one Cyclo/ALLO/miglustat-treated NPC1
2/2 mouse
cornea that showed only sporadic CLSM reflectivity (mouse
1089), we did not observe myelin-like material compared to that
found in non-treated NPC1
2/2 corneas. The superficial epithelial
Figure 3. Grading system of corneal epithelial inclusions following in vivo CLSM in Cyclo/ALLO/miglustat-treated NPC1
2/2 mice.
(A) - almost no inclusions, grade 0. (B) - isolated hyperreflective structures in the basal cell layer, less than 25% of cells are affected-grade 1. (C)-u pt o
50% of cells content hyperreflective inclusions-grade 2. (D) - for comparison, the cornea of a sham-treated NPC1
2/2 mouse - more than 75% of cells
are affected, grade 3. Bar: 50 mm. (E) - A graph, representing the number of NPC1
2/2 mice with corneal inclusions of different grades (0–3) before and
after treatment.
doi:10.1371/journal.pone.0028418.g003
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(Fig. 8A). Occasionally, some enlarged electron-lucent compart-
ments (probably Golgi cisterns) were seen in intermediate
epithelial cells (Fig. 8B, C) rather than in basal cells (Fig. 8D).
Unmyelinated nerve fibers in several areas and levels of basal
epithelium and corneal stroma were largely void of inclusions
(Fig. 8D, E). Also, keratocytes of the stroma did not show any
deposits after combined drug therapy (Fig. 8F).
Discussion
The NPC1 phenotype observed in BALB/c npc
nih mice results
from a mutation in NPC1 gene-the same gene which is responsible
for NPC1 disease in humans [27]. These mice exhibit a deficiency
of NPC1 protein with subcellular consequences, including
disturbances in sterol metabolism and trafficking [28]. Patholog-
ical features in NPC1
2/2 mice resemble those observed in late
infantile NPC1 disease in humans, exhibiting progressive neuro-
degeneration, hepatosplenomegaly and ataxia [29]. The mice
revealed excessive lipid deposition in different tissues, causing
permanent cellular damage, particularly in the nervous system,
liver, spleen, lungs and bone marrow [27]. Cholesterol and
glycosphingolipids such as GM2 and neutral glycolipids have been
reported to be predominantly accumulated in the NPC1
2/2
mouse [30,31]. Consistently, we could show accumulation of GM2
in the cornea of NPC1
2/2 mice [26]. Interestingly, no unesterified
cholesterol storage could be found in the cornea, whereas the
retina of the same mice revealed excessive accumulation of free
cholesterol [32], suggesting different storage patterns even within
different tissues.
The ophthalmological examination has been reported to be of
particular interest in NPC1 disease, because abnormal saccadic
eye movements (SEM) are one of the earliest neurological signs of
disease onset [33]. The deficit in SEM occurs both in vertical and
horizontal plane. Another sign of NPC1 disease addressing to
ocular involvement is the macular cherry red spot, which is one of
most important symptoms in the diagnosis of almost all storage
diseases [34,35]. The corneal involvement in NPC1 disease has
been only seldom reported, and even these rare data are
inconsistent, reporting in one case on corneal inclusions [36]
and in another case on normal corneal morphology without any
abnormalities [37], even though the same techniques (histology
and electron microscopy) were used in both studies. In our
previous work we demonstrated for the first time corneal
inclusions in NPC1
2/2 mice by using in vivo CLSM. The in vivo
CLSM findings were confirmed by lipid analysis and electron
microscopy [26]. The in vivo CLSM is a relatively new but very
promising approach for corneal examination in LSDs. This
technique has a big advantage to be non-invasive, thus enabling
dynamic studies in the same individuals over time. The corneal
involvement has been demonstrated by using in vivo CLSM in
patients with other LSDs, like Fabry disease, Tangier disease and
cystinosis [38–40].
On the basis of our in vivo CLSM finding about corneal
involvement in NPC1 disease, we performed the present study to
further clarify whether the regression of cellular inclusions could
Figure 4. In vivo CLSM of cornea, oblique section. (A) - normal cell morphology in NPC1
+/+ cornea. (B) - inclusions in intermediate and basal
cells in NPC1
2/2 cornea. NPC1
2/2 corneas after treatment: (C) - almost no inclusions after Cyclo/ALLO/miglustat therapy, (D) - severe inclusions with
low intensity, after Cyclo/ALLO/miglustat therapy. Bar: 50 mm.
doi:10.1371/journal.pone.0028418.g004
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combined approach has been shown to have alleviating effects in
NPC1
2/2 mice [25]. The treated NPC1
2/2 mice revealed
delayed onset of ataxic gait and tremor, increased lifespan and
significant reduction of cholesterol and ganglioside accumulation.
In good agreement with Davidson et al. (2009), [25], we visualised
the regression of accumulations in corneal epithelium of NPC1
2/2
mice. Notably, the in vivo CLSM findings varied between individual
mice, revealing an absolute remission of deposits in some animals,
and still pronounced accumulations in others. Overall, however, the
number of affected cells and intensity of inclusions were significantly
reduced in corneas of Cyclo/ALLO/miglustat-treated NPC1
2/2
mice when compared to untreated or sham-treated NPC1
2/2 mice
corneas. These findings were confirmed by lipid analysis, which
demonstrated a significant reduction of both examined isoforms of
GM2 and a slight reduction of cholesterol concentration. These
findings could be further confirmed by using electron microscopy,
which also revealed a relatively normal corneal morphology,
without apparent intracellular inclusions. It should be pointed out,
that the free cholesterol concentration differed not significantly
between both groups before treatment. This difference became,
however, statistically significant after Cyclo/ALLO/miglustat
treatment. We proposed that this might have been caused by a
more pronounced decrease of free cholesterol concentration in
NPC1
+/+ mice corneas (31% from initial values in NPC1
+/+ versus
22%inNPC1
2/2 micecorneas).Accordingly,wewouldalsoexpect
a more pronounced decrease of GM2 levels in NPC1
+/+ mice
corneas. We could not prove this, however, because the levels of
both isoforms of GM2 were lower than the limit of quantification in
NPC1
+/+ mice corneas. The main scope of our study was, however,
Figure 5. Corneal Dendritic cells in in vivo CLSM. (A) - Dendritic cells in the cornea of a NPC1
2/2 mouse before treatment. Massive
accumulation of DCs in the corneas of NPC1
2/2 (B) and NPC1
+/+ mice (C) after Cyclo/ALLO/miglustat-treatment. Also sham-treated mice revealed a
dense population of DCs (D). Bar represents 50 mm.
doi:10.1371/journal.pone.0028418.g005
Table 1. Dendritic cell number in the central cornea of NPC1
+/+ and NPC1
2/2 mice before and after treatment (Cyclo/ALLO/
miglustat or sham).
Number of DCs (cells/mm
2)
Before treatment After Cyclo/ALLO/miglustat-traetment After sham treatment
NPC1
+/+ 9634 5 653 4 63
NPC1
2/2 29657 2 665 0 64
doi:10.1371/journal.pone.0028418.t001
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Cyclo/ALLO/miglustat treatment. Biochemical analysis and
electron microscopy were performed for confirmation of in vivo
findings, and only on a limited number of animals. Future
biochemical studies with sufficient number of mice (n=6 or 8)
should be performed to clarify whether (and why) the corneas of
wild type and NPC1
2/2 mice respond differently to Cyclo/ALLO/
miglustat treatment.
Another important finding was the increase of dendritic cell
(DC) number in both treated groups. To our knowledge, one
possible explanation could be the mild allergic inflammation of
corneal surface without functional specificity. Alternatively, this
reaction could be caused by powdered chow which all mice were
fed starting at P23 until termination of experiments. The
powdered chow could have induced mechanical stress in the
cornea, leading probably to the migration of mature DCs from
the periphery to the central cornea, thus, resulting in the increase
Figure 6. Number of dendritic cells before and after treatment in NPC1
+/+ and NPC1
2/2 mouse corneas. (A) - the number of dendritic
cells in NPC1
+/+ corneas increased after Cyclo/ALLO/miglustat and sham treatment. In both cases the increase was statistically significant (p,0.0001).
(B) - also the corneas of NPC1
2/2 mice revealed a statistically significant increase in dendritic cell number both after Cyclo/ALLO/miglustat and sham
treatment (p,0.0001).
doi:10.1371/journal.pone.0028418.g006
Corneal Changes in NPC1 Disease after Therapy
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28418of DCs in the central cornea. This hypothesis could be supported
by the fact that sham-treated mice, which got their chow in
powdered form, also demonstrated an increase of DCs number
like Cyclo/ALLO/miglustat-treated ones. Nevertheless, an addi-
tional statistical analysis between sham-treated and Cyclo/
ALLO/miglustat-treated animals showed a significant difference
between two treatment options, both in NPC1
+/+ and NPC1
2/2
groups. Thus, we are inclined to believe that apart from a mild
stress, caused by powdered chow, Cyclo/ALLO/miglustat
treatment itself contributed, at least partially, to the increase of
DCs.
It is widely known that one of the most pronounced side effects
of miglustat treatment in Gaucher and NPC1 patients is the
peripheral neuropathy [41]. Immune mechanisms have been
proposed to play an important role in the development of
peripheral neuropathy in the cornea [42]. Thus, the increased
Figure 7. Levels of GM2-isoforms and free cholesterol before and after Cyclo/ALLO/miglustat-treatment. (A) - lipid analysis showed a
decrease of free cholesterol level after Cyclo/ALLO/miglustat-treatment, both in NPC1
+/+ and NPC1
2/2 mice (statistically not significant). (B) - levels of
both isoforms of GM2 revealed a statistically significant decrease in NPC1
2/2 after Cyclo/ALLO/miglustat-treatment, when compared to controls. For
both, C20-0 and C18-0 the differences were statistically significant.
doi:10.1371/journal.pone.0028418.g007
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suggesting immune-mediated contribution to the neuropathy.
Importantly, the NPC1
2/2 mice had already had a high
number of DCs before treatment, when compared to NPC1
+/+,
and also after the treatment they revealed the most pronounced
increase of DC number. This pronounced increase can be
attributed to some extent to be part of natural progression of
disease. In the future, in vivo dynamic assessment of central corneal
inflammatory cells density may provide new insights for manage-
ment of side effects and, probably, serve as an indicator of
miglustat-caused neuropathy’s severity following long-term
therapy.
Figure 8. Electron microscopical depictions of treated NPC1 mice. (A) - superficial epithelial cells of a treated NPC1
2/2 mouse without
pathological inclusions. (B) - regular cytoplasm of an intermediate epithelial cell. Rarely, somewhat enlarged profiles of Golgi compartments can be
found (asterisk, detail from C). (C) - intermediate epithelial cell with some enlarged membrane-bound compartments, presumably derived from Golgi
cisterns. (D) - basal layer of a regular corneal epithelium of NPC1
+/+ mouse. The arrows indicate axons wrapped by basal epithelial cells close to the
Bowman membrane. (E) - unmyelinated nerve fibers in the corneal stroma. Some of the fibers contain enlarged electron-light compartments with
small electron-dense corpuscles similar to that seen in B. Other cell organelles (mitochondria, neurotubules, and vesicles) are regular. Schwann cell
processes (arrows) do not contain pathological inclusions. (F) – keratocytes of the stroma show a regular aspect.
doi:10.1371/journal.pone.0028418.g008
Table 2. Comparison of HPLC/MS data with in vivo CLSM
findings.
Mouse number GM2 C20-0 GM2C18-0 In vivo CLSM
1062(NPC1
2/2) LLOQ LLOQ Grade 0
1068(NPC1
2/2) 5,15 4,37 Grade 2
1061(NPC1
2/2) 6,03 5,17 Grade 2
1087(NPC1
2/2) LLOQ LLOQ Grade 1
doi:10.1371/journal.pone.0028418.t002
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ship between ocular and extraocular symptoms are neglected in
the global evaluation of the LSD-patients. Nevertheless, the ocular
involvement can alternatively reflect other more generalized
defects in LSDs [35]. Keeping in mind the evidence that in vivo
CLSM allows the early recognition of morphological changes in
the cornea during the progression of disease or treatment course,
we believe that this technique has the potential to become an
additional clinical tool for reliable diagnosis and evaluation of
treatment options in NPC1 disorder.
Materials and Methods
Animals
All animal procedures used in this study were approved by the
Animal Use and Care Committee of the University of Rostock
(approval ID: 7221.3-1.1-088/10) and are in accordance with
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. Breeding pairs of BALB/cNctr-Npc1m1N/-J
mice were obtained from Jackson Laboratories (Bar Harbor, ME,
USA). These mice were bred to produce normal (NPC1
+/+),
heterozygous (NPC1
+/2) and homozygous affected (NPC1
2/2)
mice. All mouse pups were genotyped by using a polymerase chain
reaction (PCR) assay.
Twenty NPC1
+/+ and 20 NPC1
2/2 mice were involved in the
treatment study. Fourteen mice from each group were treated by
combined SRT and BPT- Cyclo/ALLO/miglustat. Six NPC1
+/+
and 6 NPC1
2/2 underwent sham treatment.
At the age of 65 days in vivo confocal laser-scanning microscopy
(CLSM) was performed on both eyes of each animal. Thereafter,
the animals were sacrificed by an overdose of pentobarbital, and
the excised eyes were further processed for electron microscopy or
High Performance Liquid Chromatography/Mass spectroscopy
(HPLC/MS).
Drug administration
Starting at postnatal day 7 (P7) and weekly thereafter, mice were
injected with Cyclodextrin/Allopregnanolone (25 mg/kg ALLO
dissolved in 40% CYCLO) (both from Sigma-Aldrich, Munich,
Germany). Additionally, the mice were daily injected with
miglustat, dissolved in NaCl, 300 mg/kg (miglustat was a kind
gift from Actelion Pharmaceuticals, Freiburg, Germany) at P10
until P23. Starting at P23 and until termination of experiments the
mice were fed powdered chow with daily addition of miglustat
(1200 mg/kg,). In the sham-treated group (both, NPC1
+/+ and
NPC1
2/2) the mice were injected with 50 ml 0.9% NaCl at P7
and thereafter daily, starting at P10 until P23. Like therapy group
the sham-treated mice were fed powdered chow starting at P23.
In vivo confocal laser-scanning microscopy (CLSM)
HRT II/RCM (Heidelberg Engineering GmbH, Heidelberg,
Germany) adapted for veterinary use, was used to examine the
corneas of the mice. For in vivo CLSM examination mice were
anesthetized with 2 mg/kg body weight of xylazine hydrochloride
(Rompun; Bayer HealthCare, Leverkusen, Germany) and 50 mg/
kg ketamine hydrochloride (Bela-Pharm GmbH & Co KG,
Vechta, Germany).
The laser source was a diode laser with a wavelength of 670 nm,
and the objective of the microscope was a water immersion lens
with magnification 663 (Zeiss, Hamburg, Germany). The
objective lens was fitted with a sterile polymethyle methacrylate
cap. During examination a drop of carbomer gel (Vidisic
TM,
Bausch & Lomb/Mann Pharma, Berlin, Germany) was applied as
a coupling medium between the lens cap and the cornea. The field
of view was 3846384 pixels (image size 3006300 mm) and the
focal plane could be moved through the entire cornea. Each
cornea was scanned in z-direction 6 times for collecting image
stacks, in different x-y positions in the area, including 2 mm of
central cornea. Oblique sections of the cornea were obtained by
controlling manually the x–y position and the depth of the optical
section. Each scan took approximately 20 seconds, and the overall
examination, including animal positioning and focus adjustment
time, took 10 minutes per cornea.
For quantification of dendritic cells (DCs) HRT-associated cell
count software was used. For every cornea each DC was marked
once in a predetermined area. DCs touching the border lines were
counted only along the upper and right border. DCs touching the
left and lower border, were not counted. Statistical analysis was
conducted using one side t-test for two independent samples.
Electron Microscopy
Corneas from following mice were used for transmission electron
microscopy: NPC1
+/+ (untreated control, n=1), NPC1
+/+ (treated,
n=1), NPC1
2/2 treated with no hyperreflective depositions in in
vivo CLSM (n=1) and NPC1
2/2 treated with hyperreflective
depositions in in vivo CLSM (n=1). Both corneas of each mouse
were excised and fixed in 3.7% paraformaldehyde (PFA) for 1 hour,
followedbypostfixationin0.1 Mcacodylate buffercontaining2.5%
glutaraldehyde for at least 24 hours at 4uC. Thereafter, the
specimens were osmicated, washed, block contrasted with 2%
aqueous uranyl acetate, dehydrated through a graded series of
ethanol, and embedded in Epon 812 (Plano GmbH, Marburg,
Germany). Ultrathin sections (about 70 nm) were mounted on
pioloform-coated slot copper grids and contrasted with uranyl
acetate (8 minutes) followed by lead citrate (2 min). The specimens
were examined with a Zeiss EM 902 transmission electron
microscope (Zeiss, Oberkochen, Germany) at 80 kV. Photographs
were taken using a CCD camera, scanned and adjusted using
Photoshop CS2 software.
High Performance Lipid Chromatography/Mass
spectroscopy (HPLC/MS)
For lipid analysis both corneas from randomly selected NPC1
+/+
(n=4) and NPC1
2/2 were harvested and weighed. The samples
were immediately frozen in liquid nitrogen and stored at 280uC
until further analysis. Both corneas for each animal were pooled to
form one sample. Total lipid extractions were obtained by using
ultrasonic tissue disintegration for 2 minutes. Total lipids were
extracted into ethanolic solution of internal standard (deuterated).
Thereafter HPLC/MS was carried out on a C8 column (ACE 3C8,
5062.1 mm) for determination of free cholesterol and 2 different
isoforms (C20-0 and C18-0) of disialotetrahexosylganglioside 2
(GM2). The values were expressed as mg per g wet weight of tissue
(mg/g).Forstatistical analysisnon-parametric U-testwasperformed.
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